However, recent studies demonstrating the physical interaction between the mitotic kinase AURKA and N-Myc sequesters the latter from proteolytic degradation [7,17], paved the way for a novel, promising chemotherapeutic approach in neuroblastoma. The gene discussed is MYCN; the disease is neuroblastoma.